Cargando…
Event-free survival following early endometrial events in breast cancer patients treated with anti-hormonal therapy: A nationwide claims data study
Tamoxifen, an anti-estrogen agent that can suppress breast cancer, has been reported to increase endometrium-related adverse events. There are no guidelines for screening tamoxifen-treated patients for endometrial disease. We analyzed nationwide claims data related to endometrial diseases to investi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336644/ https://www.ncbi.nlm.nih.gov/pubmed/30633178 http://dx.doi.org/10.1097/MD.0000000000013976 |